This clinical trial is focused on studying the effectiveness of a medication called methoxyflurane in managing pain for patients experiencing an Acute Myocardial Infarction, commonly known as a heart attack. The study will compare methoxyflurane to another pain relief medication, morphine, to see if methoxyflurane can provide similar pain relief with better tolerance. Methoxyflurane is administered through inhalation, while morphine is given as an intravenous bolus, which means it is injected directly into a vein.
The purpose of the study is to determine if methoxyflurane, when self-administered by patients, can effectively relieve chest pain associated with a heart attack. Participants in the study will receive either methoxyflurane or morphine to manage their pain. The study will monitor how quickly and effectively each medication relieves pain and will also assess the impact on the cardiovascular system, including heart rate and blood pressure, as well as any side effects such as dizziness, nausea, or respiratory issues.
The trial will take place in a pre-hospital setting, meaning it will be conducted before patients reach the hospital. The study aims to provide valuable information on whether methoxyflurane can be a viable alternative to morphine for pain management in heart attack patients, potentially offering a more comfortable experience with fewer side effects. The trial is expected to run until 2028, with recruitment starting in 2025.



France